Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of IPG1094 in Healthy Adult Participants
NCT05112159Phase 1Completed
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd.
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IPG1094 (10 arms), sponsored by Nanjing Immunophage Biotech Co., Ltd. Primary endpoint: Adverse Events. Started Sep 2021; status: completed.
02
Drugs
IPG1094
Beyond the preview
Go deeper on NCT05112159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05112159.